Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daratumumab/hyaluronidase - Janssen Biotech

Next Previous
X
Search
Drug Profile

Daratumumab/hyaluronidase - Janssen Biotech

Alternative Names: DARA-PH20; DARA-SC; daratumumab and hyaluronidase-fihj; Daratumumab subcutaneous - Janssen Biotech; DARZALEX FASPRO; DARZALEX SC; DARZALEX-SC; Darzquro; Recombinant human hyaluronidase-based subcutaneous daratumumab

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Biotech
  • Developer Janssen Research & Development; Johnson & Johnson Innovative Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid light-chain amyloidosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Amyloid light-chain amyloidosis; Multiple myeloma
  • Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 30 Jul 2024 Registered for Multiple myeloma (Combination therapy, Newly diagnosed) in USA (SC)
  • 30 Jul 2024 Updated efficacy data from a phase III PERSEUS trial in Multiple myeloma released by Janssen Research & Development
  • 31 May 2024 Updated efficacy data from the phase III PERSEUS trial in Multiple myeloma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top